NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$96.55 -4.99 (-4.91 %)
(As of 10/23/2018 02:19 PM ET)
Previous Close$101.54
Today's Range$93.77 - $97.41
52-Week Range$90.31 - $116.49
Volume123,221 shs
Average Volume1.08 million shs
Market Capitalization$14.01 billion
P/E Ratio17.64
Dividend Yield1.95%
Beta0.73
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNYSE:DGX
Previous Symbol
CUSIP74834L10
Phone973-520-2700

Debt

Debt-to-Equity Ratio0.65
Current Ratio1.12
Quick Ratio1.05

Price-To-Earnings

Trailing P/E Ratio17.64
Forward P/E Ratio14.65
P/E Growth1.95

Sales & Book Value

Annual Sales$7.71 billion
Price / Sales1.71
Cash Flow$6.9611 per share
Price / Cash13.87
Book Value$36.35 per share
Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)$5.40
Net Income$772 million
Net Margins10.56%
Return on Equity15.45%
Return on Assets7.33%

Miscellaneous

Employees45,000
Outstanding Shares136,670,000
Market Cap$14.01 billion
OptionableN/A

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Friday, August 17th. Investors of record on Friday, October 5th will be given a dividend of $0.50 per share on Monday, October 22nd. This represents a $2.00 annualized dividend and a yield of 2.10%. The ex-dividend date is Thursday, October 4th. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its board has authorized a stock buyback program on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 7.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) issued its quarterly earnings results on Tuesday, October, 23rd. The medical research company reported $1.68 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $1.68. The medical research company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.95 billion. Quest Diagnostics had a net margin of 10.56% and a return on equity of 15.45%. The firm's revenue was up 1.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.38 EPS. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, October 23rd 2018. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY18 earnings guidance on Tuesday, October, 23rd. The company provided EPS guidance of $6.53-6.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.60. The company issued revenue guidance of ~$7.62 billion, compared to the consensus revenue estimate of $7.71 billion.Quest Diagnostics also updated its FY 2018 guidance to $6.53-6.60 EPS.

What price target have analysts set for DGX?

16 equities research analysts have issued 1 year price targets for Quest Diagnostics' stock. Their predictions range from $98.00 to $130.00. On average, they expect Quest Diagnostics' share price to reach $114.75 in the next year. This suggests a possible upside of 20.4% from the stock's current price. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quest Diagnostics.

Who are some of Quest Diagnostics' key competitors?

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 43)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.21%), State of Alaska Department of Revenue (0.15%), Hardman Johnston Global Advisors LLC (0.14%), Chevy Chase Trust Holdings Inc. (0.08%), Andra AP fonden (0.07%) and Aperio Group LLC (0.06%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC, Aperio Group LLC, Texas Permanent School Fund, Chevy Chase Trust Holdings Inc., CenturyLink Investment Management Co, Huntington National Bank, Hardman Johnston Global Advisors LLC and Krueger & Catalano Capital Partners LLC. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which major investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including Seven Eight Capital LP, Pensionfund DSM Netherlands, Bank of Montreal Can, Pensionfund Sabic, State of Alaska Department of Revenue, Andra AP fonden, First Citizens Bank & Trust Co. and Nisa Investment Advisors LLC. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $95.28.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $14.01 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  635 (Vote Underperform)
Total Votes:  987
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Featured Article: Fundamental Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel